Skip to main content

Table 2 Indications for withholding and recommencement of nebulised heparin

From: The CHARTER-Ireland trial: can nebulised heparin reduce acute lung injury in patients with SARS-CoV-2 requiring advanced respiratory support in Ireland: a study protocol and statistical analysis plan for a randomised control trial

Nebulised heparin should be withheld if any of the following occurs:

Nebulised heparin should be recommenced if:

More than 10 days have elapsed since randomisation

Having been withheld because the patient was outside the ICU, the patient returns to ICU

The patient is outside of higher-level care setting

Having been withheld because the patient was not receiving advanced respiratory support, advanced respiratory support is reinstituted

The patient is not receiving advanced respiratory support

Having been withheld because the APTT was unacceptably prolonged, the APTT becomes acceptable

The treating physician deems that there is a clinically unacceptable increase in APTT (>100s)

Having been withheld because there was excessive bloodstaining of respiratory secretions, the bloodstaining of the respiratory secretions has resolved

The treating physician deems that there is excessive bloodstaining of respiratory secretions

Having been withheld for suspected HIT, the patient is found not to have this condition

There is pulmonary bleeding, major bleeding or suspected or confirmed HIT

Having been withheld for ECMO, the treatment with ECMO is stopped

The patient is receiving ECMO or HFOV

Having been withheld for HFOV, the treatment with HFOV is stopped